Literature DB >> 30811976

HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis.

Florinda Meléndez-Rodríguez1, Andrés A Urrutia2, Doriane Lorendeau3, Gianmarco Rinaldi3, Olga Roche4, Nuray Böğürcü-Seidel5, Marta Ortega Muelas6, Claudia Mesa-Ciller2, Guillermo Turiel2, Antonio Bouthelier2, Pablo Hernansanz-Agustín2, Ainara Elorza2, Elia Escasany2, Qilong Oscar Yang Li2, Mar Torres-Capelli2, Daniel Tello2, Esther Fuertes2, Enrique Fraga2, Antonio Martínez-Ruiz1, Belen Pérez7, Jose Miguel Giménez-Bachs8, Antonio S Salinas-Sánchez8, Till Acker5, Ricardo Sánchez Prieto9, Sarah-Maria Fendt3, Katrien De Bock10, Julián Aragonés11.   

Abstract

Cellular aspartate drives cancer cell proliferation, but signaling pathways that rewire aspartate biosynthesis to control cell growth remain largely unknown. Hypoxia-inducible factor-1α (HIF1α) can suppress tumor cell proliferation. Here, we discovered that HIF1α acts as a direct repressor of aspartate biosynthesis involving the suppression of several key aspartate-producing proteins, including cytosolic glutamic-oxaloacetic transaminase-1 (GOT1) and mitochondrial GOT2. Accordingly, HIF1α suppresses aspartate production from both glutamine oxidation as well as the glutamine reductive pathway. Strikingly, the addition of aspartate to the culture medium is sufficient to relieve HIF1α-dependent repression of tumor cell proliferation. Furthermore, these key aspartate-producing players are specifically repressed in VHL-deficient human renal carcinomas, a paradigmatic tumor type in which HIF1α acts as a tumor suppressor, highlighting the in vivo relevance of these findings. In conclusion, we show that HIF1α inhibits cytosolic and mitochondrial aspartate biosynthesis and that this mechanism is the molecular basis for HIF1α tumor suppressor activity.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GOT1; GOT2; HIF1α; aspartate biosynthesis; cancer; glutamine; oxygen; proliferation; renal cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 30811976     DOI: 10.1016/j.celrep.2019.01.106

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  26 in total

1.  Hypoxia signaling: Challenges and opportunities for cancer therapy.

Authors:  Mircea Ivan; Melissa L Fishel; Oana M Tudoran; Karen E Pollok; Xue Wu; Paul J Smith
Journal:  Semin Cancer Biol       Date:  2021-10-07       Impact factor: 15.707

2.  Expression of GOT2 Is Epigenetically Regulated by DNA Methylation and Correlates with Immune Infiltrates in Clear-Cell Renal Cell Carcinoma.

Authors:  Wallax Augusto Silva Ferreira; Edivaldo Herculano Correa de Oliveira
Journal:  Curr Issues Mol Biol       Date:  2022-05-25       Impact factor: 2.976

Review 3.  The effect of HIF on metabolism and immunity.

Authors:  Cormac T Taylor; Carsten C Scholz
Journal:  Nat Rev Nephrol       Date:  2022-06-20       Impact factor: 42.439

4.  Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming.

Authors:  Muhua Chen; Chunfeng Zhang; Wei Liu; Xiaojuan Du; Xiaofeng Liu; Baocai Xing
Journal:  Mol Ther       Date:  2022-02-19       Impact factor: 12.910

Review 5.  The functional roles of TCA cycle metabolites in cancer.

Authors:  Joseph Eniafe; Shuai Jiang
Journal:  Oncogene       Date:  2021-04-16       Impact factor: 9.867

6.  Mesenchymal stem cell-derived microvesicles improve intestinal barrier function by restoring mitochondrial dynamic balance in sepsis rats.

Authors:  Tao Li; Liangming Liu; Danyang Zheng; Henan Zhou; Hongchen Wang; Yu Zhu; Yue Wu; Qinghui Li
Journal:  Stem Cell Res Ther       Date:  2021-05-26       Impact factor: 6.832

7.  A HIF1α-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism.

Authors:  Ren Liu; Yuanfa Feng; Yulin Deng; Zhihao Zou; Jianheng Ye; Zhiduan Cai; Xuejin Zhu; Yingke Liang; Jianming Lu; Hui Zhang; Yong Luo; Zhaodong Han; Yangjia Zhuo; Qingling Xie; Chi Tin Hon; Yuxiang Liang; Chin-Lee Wu; Weide Zhong
Journal:  J Exp Clin Cancer Res       Date:  2021-06-07

8.  KLF4K409Q-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment.

Authors:  Niklas von Spreckelsen; Natalie Waldt; Rebecca Poetschke; Christoph Kesseler; Hildegard Dohmen; Hui-Ke Jiao; Attila Nemeth; Stefan Schob; Cordula Scherlach; Ibrahim Erol Sandalcioglu; Martina Deckert; Frank Angenstein; Boris Krischek; Pantelis Stavrinou; Marco Timmer; Marc Remke; Elmar Kirches; Roland Goldbrunner; E Antonio Chiocca; Stefan Huettelmaier; Till Acker; Christian Mawrin
Journal:  Acta Neuropathol Commun       Date:  2020-04-03       Impact factor: 7.801

9.  Network-based metabolic characterization of renal cell carcinoma.

Authors:  Nishtha Pandey; Vinay Lanke; P K Vinod
Journal:  Sci Rep       Date:  2020-04-06       Impact factor: 4.379

Review 10.  Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion.

Authors:  Peter Kreuzaler; Yulia Panina; Joanna Segal; Mariia Yuneva
Journal:  Mol Metab       Date:  2019-10-10       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.